



**Supplementary material**

---

**Red Cell Distribution Width and Additive Risk Prediction for Major Bleeding in Non–ST-segment Elevation Acute Coronary Syndrome**

Marianela Sánchez-Martínez,<sup>a</sup> Ángel López-Cuenca,<sup>b</sup> Francisco Marín,<sup>a</sup>  
Pedro J. Flores-Blanco,<sup>a</sup> Andrea García Narbon,<sup>b</sup> Jose I. de las Heras-Gómez,<sup>b</sup>  
María J. Sánchez-Galian,<sup>a</sup> Mariano Valdes,<sup>a,d</sup> James L. Januzzi,<sup>e</sup>  
and Sergio Manzano-Fernández<sup>a,d,\*</sup>

<sup>a</sup>*Departamento de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain*

<sup>b</sup>*Departamento de Medicina Interna, Hospital de la Vega Lorenzo Guirao, Cieza, Murcia, Spain*

<sup>c</sup>*Departamento de Bioquímica, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain*

<sup>d</sup>*Universidad de Murcia, Murcia, Spain*

<sup>e</sup>*Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, United States*

---

**Table 1**

Study Population Clinical Characteristics as a Function of Red Cell Distribution Width Quartiles

RDW %					
Variables	Q1 N = 85	Q2 N = 75	Q3 N = 66	Q4 N = 67	P
Range	12 to 13.2%	13.3 vto 13.9%	14 to 14.9%	15 to 21.8%	
Age, mean (SD), y	65 (13)	69 (11)	68 (11)	71 (12)	.03
Age >75 years	24 (28)	27 (36)	19 (29)	28 (42)	.17
Sex (male)	66 (78)	58 (77)	40 (61)	38 (57)	.001
Body mass index, mean (SD), Kg/m <sup>2</sup>	29 (3)	29 (4)	29 (4)	30 (5)	.38
Systolic blood pressure, mmHg	140 [121-160]	137 [122-156]	140 [125-15]	140 [121-166]	.68
Heart rate, beat/min	70 [60-80]	78 [67-90]	79 [70-93]	80 [72-100]	<.001
Diabetes mellitus	39 (46)	25 (33)	36 (55)	44 (66)	.003
Hypertension	60 (71)	61 (81)	51 (77)	64 (96)	.001
Hyperlipidemia	42 (49)	43 (57)	45 (68)	45 (67)	.010
Current smoking	20 (24)	25 (33)	18 (27)	9 (13)	.14
Previous non-ST elevation ACS	29 (34)	20 (27)	13 (20)	25 (37)	.99

Previous STEMI	24 (28)	8 (11)	9 (14)	17 (25)	.63
Atrial fibrillation/flutter	5 (6)	6 (8)	7 (11)	9 (13)	.09
Previous stroke	7 (8)	4 (5)	4 (6)	13 (19)	.04
Previous heart failure	5 (5)	2 (3)	1 (1.5)	6 (9)	.33
Ejection Fraction	60 [50-65]	60 [51-67]	60 [50-65]	59 [45-65]	.52
Ejection Fraction > 50%	60 (76)	60 (85)	49 (77)	46 (70)	.27
Peripheral artery disease	5 (6)	9 (12)	4 (6)	10 (15)	.15
eGFR, mL/min/1.73 <sup>2</sup>	79 [63-109]	73 [59-96]	73 [59-102]	62 [48-91]	.008
Hemoglobin, mean (SD), g/dL	14.4 (1.4)	14.2 (1.5)	13.6 (1.8)	12.3 (2.2)	<.001
Hematocrit, mean (SD), %	45 (4)	42 (5)	40 (6)	36 (6)	<.001
MCV, mean (SD), fL	89 (4)	90 (4)	89 (5)	84 (7)	<.001
Troponin T, ng/mL	0.06 [0.01-0.07]	0.06 [0.01-0.51]	0.09 [0.01-1.67]	0.03 [0.01-0.23]	.41
C- reactive protein (mg/dL)	0.5 [0.2-1.4]	0.6 [0.3-4.1]	0.7 [0.4-3.1]	1.1 [0.4-3.2]	.05
CRUSADE risk score, mean (SD)	24 (13)	26 (13)	30 (15)	38 (15)	<.001
Number of vessel disease 0-VD / 1-VD / 2-VD / 3- VD±LMD	8 (13)/ 23 (38)/ 17 (28)/ 12 (20)	9 (16)/ 15 (30)/ 12 (24)/ 15 (30)	3 (8)/13 (33)/ 9 (23)/14 (36)	6 (17)/3 (8)/ 11 (31)/16 (44)	.12
Revascularization	59 (69)	53 (71)	47 (71)	31 (46)	.008
PCI-S / CABG	54 (64) / 5	47 (63) / 6 (8)	43 (65) / 4 (6)	25 (37) / 6 (9)	.24

DES / BMS	(6)	39 (52) / 8	36 (55) / 7 (11)	18 (27) / 6 (9)	.15
Femoral vascular access	49 (56) / 6	(11)	17 (26)	21 (31)	.35
Use of Iib/IIIa glycoprotein inhibitors	(7) 26 (31) 9 (11)	17 (23) 7 (9)	7 (11)	2 (3)	.27
Final diagnosis: UA / NSTEMI	25 (29) / 60 (71)	2 (29) / 53 (71)	21 (32) / 45 (68)	24 (36) / 43 (64)	.38
Aspirin	78 (96)	72 (96)	64 (100)	58 (92)	.45
Clopidogrel	72 (89)	63 (84)	54 (84)	44 (70)	.006
•-blocker	72 (89)	68 (91)	55 (86)	56 (89)	.78
ACE inhibitors/ARB	70 (86)	67 (89)	56 (88)	55 (87)	.94
Statin	78 (96)	74 (99)	62 (97)	60 (95)	.64
Acenocumarol	4 (5)	3 (4)	6 (9)	7 (11)	.09

Unless otherwise indicated, the data are expressed No. (%).

ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin-receptor blocker; BMS, bare metal stent; CABG, coronary artery bypass graft; DES, drug eluting stent; eGFR, glomerular filtration rate; STEMI, ST segment elevation myocardial infarction; LMD, left main disease; NSTEMI, non-ST segment elevation myocardial infarction; PCI-S, percutaneous coronary intervention with stent implantation; STEMI, ST segment elevation myocardial infarction, UA, unstable angina; VD, vessel disease,